Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER - Authors' reply
- PMID: 32738950
- DOI: 10.1016/S0140-6736(20)30534-1
Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER - Authors' reply
Comment on
-
Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER.Lancet. 2020 Aug 1;396(10247):311. doi: 10.1016/S0140-6736(20)30545-6. Lancet. 2020. PMID: 32738951 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
